AstraZeneca PLC American Depositary Shares (AZN)
NASDAQ (NGS) NASDAQ (NGS) Primary 
Do Options Traders Know Something About AstraZeneca Stock We Don't?
Investors need to pay close attention to AZN stock based on the movements in the options market lately.
Deal or No Deal, AstraZeneca Stock Is a Bargain
The logic of a pharma megamerger is questionable, but AstraZeneca's record isn't.
Brokers split on AstraZeneca merger talk as shares recover some ground
Citi has told clients that a large chunk of deal risk is already in AstraZeneca PLC's (LSE:AZN, NASDAQ:AZN) share price after Monday's sharp fall, while Deutsche Bank sees clear parallels with the drugmaker's Alexion acquisition five years ago. The two notes are the second-day response to a Financial Times report over the weekend that the FTSE 100 drugmaker is in discussions over a merger with US rival Bristol Myers Squibb.
More Biotech M&A Is on the Way, Whether an AstraZeneca-Bristol Myers Deal Happens or Not
Even if a megamerger fails to materialize, investors stand to benefit from a wave of M&A activity in the biopharma sector.
Top Healthcare Analyst: A $400 Billion AstraZeneca-Bristol Myers Deal Could “Cut Costs in a Big Way”
Holz framed the logic bluntly. “If you take these two companies and you slash expenses, that would be the main thing here.
Bristol-Myers stock: why AstraZeneca merger is unlikely to happen
Bristol-Myers Squibb (BMY) stock is declining this morning, reversing its premarket gains as Wall Street digests bombshell reports of a potential transatlantic merger with AstraZeneca (AZN). According to media reports, the UK healthcare heavyweight has held preliminary discussions with BMY regarding a potential megamerger that could value the combined enterprise near $400 billion.
Bristol Myers Squibb Stock Jumps on Reported Merger Talks With AstraZeneca
Bristol Myers Squibb stock is surging Monday following a report of a potential mega-merger with a competitor.
Analysts baffled by AstraZeneca's interest in Bristol Myers Squibb
AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) shares fell 6% to 11,872p on Monday, the steepest decline in the FTSE 100, as analysts struggled to explain why Britain's largest drugmaker would want to buy Bristol-Myers Squibb Co (NYSE:BMY, XETRA:RM, OTC:BMYMP). Jefferies described the reported talks as more than a 'head scratcher'.
AstraZeneca tie-up talks with Bristol-Myers Squibb are moving stocks. Analysts are puzzled.
AstraZeneca shares were slumping while Bristol-Myers Squibb was jumping on Monday on reported deal talks. But the big question is why these two pharmaceutical giants would want to come together in the first place.
Bristol Myers Squibb Stock Soars on Report of $400 Billion Merger Talks With AstraZeneca
The merger would be one of the biggest pharma deals ever. AstraZeneca's market capitalization stood at $264 billion as of Friday's close, while Bristol Myers Squibb had a total valuation of $133 billion.
Why did AstraZeneca shares fall 6% after Bristol Myers Squibb merger reports?
AstraZeneca shares fell more than 6% in early trading on Monday after reports emerged that the British pharmaceutical giant had held preliminary discussions with US-based Bristol Myers Squibb over a potential merger, a move that could create one of the world's largest drugmakers. A person familiar with the matter told Reuters that the companies had explored a possible combination, confirming an earlier report by the Financial Times.
AstraZeneca shares slide 7% on talks to buy Bristol Myers Squibb
Shares in AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) fell 7% to 11,723p on Monday after news that Britain's biggest drugmaker is in talks to buy its US rival, Bristol-Myers Squibb Co (NYSE:BMY, XETRA:RM, OTC:BMYMP). A deal would create a pharmaceutical group worth close to $400 billion, ranking fourth in the industry by market value.
